
FDA - BPC If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before X 1, Y then the market resolves to Yes. The Payout Criterion is satisfied by placement of BPC-157 in either Category 1 or Category 1 Bulk Drug Substances Under Evaluation on the 503A Bulk Drug Substances list, as either designation restores compounding eligibility. Removal from Category 2 alone, without placement in Category 1, does not satisfy the Payout Criterion. This market will
83%
$0.00
5

83%
$0.00
5
5 markets tracked
No data available
| Market | Price |
|---|---|
When will FDA announce Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List? (Before 2027) | 83% |
When will FDA announce Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List? (Before November) | 82% |
When will FDA announce Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List? (Before September) | 77% |
When will FDA announce Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List? (Before July) | 22% |
When will FDA announce Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List? (Before May) | 6% |